Company Profile
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Latest News
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
Earnings Calendar and Analysis for This Week (July 27-31)
Hamilton Lane Board Elects Michael Schmertzler as New Independent Director
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.ptcbio.com |
| Audit Risk | 3 |
| Board Risk | 3 |
| Overall Risk | 4 |
| Market Cap | 6.37B |
| Forward P/E | 28.04 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -2.54 |
| Forward EPS | 2.74 |
| Book Value | -2.18 |
| Enterprise-to-Revenue | 8.71 |
| Enterprise-to-EBITDA | -344.58 |
| Short Ratio | 3.61 |
| Earnings Date | 07/30/2026 |
| Earnings Call Date | 07/30/2026 |
| Earnings Average | 0.34 |
| Earnings Low | 0.17 |
| Earnings High | 0.56 |
| Revenue Average | 298.63M |
| Revenue Low | 264.22M |
| Revenue High | 340.59M |